One in six health systems with top AI returns reports AI-related layoffs
Nov 15, 2026
Listen to this post
read by AI voices · all episodesOne in six of the U.S. hospitals and health systems earning the most from artificial intelligence reported AI-related layoffs, according to a Vizient survey of 416 senior leaders released Nov. 12.
The survey put the average return on AI deployments at 3.2 times their cost, a self-reported estimate, with the largest returns in pharmacy, supply chain and utilization management. State medical boards, meanwhile, plan to publish draft guidance in December on physician accountability when AI performs clinical work, the Federation of State Medical Boards and the American Medical Association said.
Two more measles deaths, in Pennsylvania and Wisconsin, brought this year's U.S. toll to 10, a day after the country lost its measles elimination status, and Congo's Ebola outbreak passed 11,000 cases.
- FYIWorkforce Nov 12, 2026Seventeen percent of the hospitals and health systems reporting the highest returns on artificial intelligence said they had made AI-related layoffs, according to a Vizient survey of 416 senior leaders at 385 U.S. acute care organizations released Nov. 12. Among those top performers, 59% redesigned roles, 56% redeployed staff to other work, 53% cut overtime and 21% reduced headcount through attrition. Deployments returned a mean of 3.2 times their cost and a median of 2.5 times; pharmacy, supply chain and utilization management reached a median of 3.0 times, while clinical care, care management and patient access returned closer to 2 times despite adoption rates of 71% to 92%. The returns are self-reported estimates that include time savings and quality gains and were not independently verified, Vizient said. The survey was fielded in April and May.Sources: Vizient, Becker's Hospital Review
- WatchRegulation Nov 12, 2026
The federation plans to release its draft guidance for public comment in December 2026 and a delegate vote in April 2027.
The Federation of State Medical Boards' AI workgroup plans to release draft guidance and recommendations for public comment in December 2026, with a vote by the federation's House of Delegates planned for April 2027, according to a Nov. 12 announcement with the American Medical Association. The two groups published proceedings from a Sept. 14 forum in Washington of more than 200 physicians, board representatives, patients, policymakers and technology developers on autonomous and semiautonomous AI. Participants concluded that licensure, regulatory and liability frameworks were not built for AI, and listed as priorities clarifying when AI is a clinical tool and when it constitutes the practice of medicine, and how responsibility for AI-related harm is assigned among boards, regulators, developers and physicians. "State medical boards exist to protect patients, and that mission does not change as the tools of medicine change," said Dr. Humayun Chaudhry, the federation's president and CEO. Dr. John Whyte, the AMA's CEO, said "there is a difference between automating medical tasks and automating medicine itself." - FYIIncident Nov 14, 2026Pennsylvania and Wisconsin each reported a measles-associated death on Nov. 13, one of them an infant in Wisconsin, bringing the U.S. total for 2026 to 10, Al Jazeera reported. Pennsylvania has now recorded seven deaths, and the patient there was unvaccinated. The CDC's website lists six measles-related deaths, and the agency said it is working with the Council of State and Territorial Epidemiologists on a standard definition. The deaths follow the Pan American Health Organization's finding of uninterrupted transmission for more than 12 months, which ended the elimination status the United States had held since 2000, with more than 5,400 confirmed cases this year. Kindergarten vaccination coverage fell to 92.4% in the 2025-26 school year from 95.2% in 2019-20, according to the report.Source: Al Jazeera
- FYIIncident Nov 11, 2026Congo's health ministry reported 11,042 Ebola cases and 5,387 deaths on Nov. 11 in an outbreak declared in mid-May, now in eight of the country's 26 provinces with Ituri and North Kivu as hotspots, The Associated Press reported. The virus has also reached Uganda, Kenya and Nigeria. The outbreak is caused by Bundibugyo virus, which has no known vaccine or treatment, according to the report. U.S. rules require foreign travelers to certify they have not been in Congo in the prior three weeks, Becker's Hospital Review reported in October.
- FYIEvidence Nov 13, 2026A deep learning model applied to the ECG detected and predicted dilated cardiomyopathy with performance comparable to echocardiography, researchers led by Imperial College London reported Nov. 13 in the European Heart Journal. Trained on more than 330,000 ECG-echocardiogram pairs from Beth Israel Deaconess Medical Center, the model had areas under the curve of 0.87 to 0.97 for existing disease in validation cohorts from the UK Biobank, Zhongshan Hospital in Shanghai and Antwerp University Hospital, and C-indexes of 0.80 to 0.87 for future disease, against 0.80 to 0.90 for echocardiography. In 343 genetically predisposed relatives found through cascade screening in Antwerp and Maastricht, 5-year negative predictive values were 95.5% and 91.5%, positive predictive values were 42.4% and 39.4%, and high-risk scores carried a 5.1- to 6.4-fold risk of incident disease. The authors said the low-cost tool could reduce surveillance burden; the study validated accuracy and did not test the model's use in care.Sources: European Heart Journal, PubMed
- FYIRegulation Nov 12, 2026The Drug Enforcement Administration placed oveporexton, sold as Orzeyful, in Schedule IV of the Controlled Substances Act in an interim final rule that took effect on publication Nov. 12. The FDA approved the drug Aug. 5, 2026, for narcolepsy type 1 in adults. The rule adds the drug at 21 CFR 1308.14, and comments are due 30 days after publication.
- FYIEvidence Nov 14, 2026Once-weekly cagrilintide-semaglutide at 1.7 mg each or 1.0 mg each reduced body weight 20.7% and 21.0% at 68 weeks, against 2.0% with placebo, in REDEFINE 9, a randomized, double-blind phase 3b trial of 309 adults without diabetes who had a BMI of 30 or more, or 27 or more with an obesity-related complication, published Nov. 14 in The Lancet Diabetes & Endocrinology. Weight loss of at least 5% occurred in 95.1% and 96.3% of the two dose groups versus 33.4% on placebo. Adverse events, mostly mild or moderate and gastrointestinal, occurred in 99% and 95% of the treated groups and 91% on placebo, and no deaths were reported. The figures use the efficacy estimand; earlier phase 3 trials tested 2.4 mg each, and Novo Nordisk funded the study.Sources: The Lancet Diabetes & Endocrinology, PubMed